iBio Inc
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2008-04-01
- Employees
- 23
- Market Cap
- $16.5M
- Website
- http://www.ibioinc.com
- Introduction
iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.
Clinical Trials
0
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
News
iBio Advances AI-Driven Obesity Pipeline with Myostatin and Activin E Antibody Therapies
iBio will present promising preclinical data on its long-acting Myostatin antibody IBIO-600 and Activin E targeting therapies for obesity and cardiometabolic diseases.
UIC Researchers Develop Groundbreaking Antibiotic Against Superbugs as Illinois Faces Rising Antimicrobial Resistance
University of Illinois Chicago researchers have developed a novel antibiotic that could make it 100 million times harder for bacteria to develop resistance, potentially revolutionizing treatment of drug-resistant infections.
iBio Licenses First-in-Class Antibody Targeting Activin E for Obesity and Cardiometabolic Diseases
iBio has secured a licensing agreement with AstralBio for a preclinical first-in-class antibody targeting Activin E, discovered using iBio's patented Machine-Learning Antibody Engine.
FDA Budget Cuts Under Trump Administration Threaten Drug Development Pipeline
• Pharmaceutical companies warn in SEC filings that Trump administration's FDA staffing and budget cuts could significantly delay or halt new drug approvals and commercialization processes. • Recent layoffs of hundreds of FDA employees have sparked industry-wide concerns about disruptions to clinical trials, grant applications, and regulatory oversight activities. • Multiple biotech firms, including Xenon Pharmaceuticals and Rezolute, report that reduced FDA capacity could negatively impact their drug development timelines and business operations.